DSP Healthcare Fund
The portfolio is tightly positioned for pharmaceutical and biotech exposure, with nearly two-thirds concentrated in that sector and top holdings dominated by established drugmakers and emerging life sciences players. The manager's March rebalancing—trimming IPCA while significantly building Cohance—signals conviction in high-growth, niche biotech names over larger incumbents, suggesting a tilt toward innovation-driven upside. At 65% in top-10 holdings, this is a conviction-heavy fund betting on a narrow set of healthcare winners rather than broad sector diversification.
Portfolio analysis · April 2026
NAV & Returns
| Plan | NAV | 1M | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Direct Growth | ₹44.7340 | — | — | — | — |
| Regular Growth | ₹40.0930 | +6.67% | +8.31% | +22.37% | +14.16% |
| Direct IDCW | ₹25.8690 | — | — | — | — |
| Regular IDCW | ₹23.2250 | — | — | — | — |
Portfolio Metrics(latest month)
vs Category Peers
Highly DifferentiatedActive Share = ½Σ|wfund − wpeer|, computed using leave-one-out peer portfolio within SEBI category.
Similar Funds in Category
What Changed2026-03-31 → 2026-04-30
| Stock | Weight | |
|---|---|---|
| No new entries this month | ||
Full Holdings
| # | Holding | % to NAV |
|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited INE044A01036 | 8.84% |
| 2 | IPCA Laboratories Limited INE571A01038 | 8.26% |
| 3 | Cipla Limited INE059A01026 | 7.56% |
| 4 | Globus Medical Inc US3795772082 | 7.35% |
| 5 | Laurus Labs Limited INE947Q01028 | 6.42% |
| 6 | Illumina Inc US4523271090 | 6.16% |
| 7 | Sai Life Sciences Limited INE570L01029 | 6.10% |
| 8 | Gland Pharma Limited INE068V01023 | 5.13% |
| 9 | Cohance Lifesciences Limited INE03QK01018 | 4.83% |
| 10 | Apollo Hospitals Enterprise Limited INE437A01024 | 4.73% |
| 11 | Alembic Pharmaceuticals Limited INE901L01018 | 3.43% |
| 12 | Vijaya Diagnostic Centre Limited INE043W01024 | 3.36% |
| 13 | Pfizer Limited INE182A01018 | 3.01% |
| 14 | Kovai Medical Center and Hospital Limited INE177F01017 | 2.97% |
| 15 | Procter & Gamble Health Limited INE199A01012 | 2.64% |
| 16 | Intuitive Surgical Inc US46120E6023 | 2.60% |
| 17 | TREPS / Reverse Repo Investments | 2.19% |
| 18 | Indoco Remedies Limited INE873D01024 | 2.16% |
| 19 | Emcure Pharmaceuticals Limited INE168P01015 | 2.01% |
| 20 | Concord Biotech Limited INE338H01029 | 1.81% |
Sector Allocation
Top 10 sectors by % to NAV. Excludes derivatives.
Frequently Asked Questions
How many stocks does DSP Healthcare Fund hold?
DSP Healthcare Fund holds 31 stocks as per the latest AMFI portfolio disclosure. The top 5 positions account for 38.43% of NAV.
What is the largest holding in DSP Healthcare Fund?
The largest position in DSP Healthcare Fund is Sun Pharmaceutical Industries Limited, accounting for 8.84% of NAV in the Pharmaceuticals & Biotechnology sector.
Is DSP Healthcare Fund a concentrated or diversified fund?
With a Gini coefficient of 0.463, DSP Healthcare Fund is moderately concentrated. The HHI concentration index is 52,008 bps, which is above the 2500 bps threshold for high concentration. The top 5 holdings together make up 38.43% of the portfolio.
What is the market cap allocation of DSP Healthcare Fund?
Based on SEBI's AMFI classification, DSP Healthcare Fund's equity portfolio is split as: Large Cap: 21.13%, Mid Cap: 16.67%, Small Cap: 41.83%. This reflects the fund's positioning within the market cap spectrum.
Which sectors does DSP Healthcare Fund invest in most?
DSP Healthcare Fund has the highest allocation to Pharmaceuticals & Biotechnology (65.94%), Healthcare Services (18.80%), Healthcare Equipment & Supplies (10.13%). The fund is invested across 6 sectors in total.
How actively managed is DSP Healthcare Fund compared to other Sectoral / Thematic funds?
DSP Healthcare Fund has an Active Share of 93.31%, classifying it as "Highly Differentiated" among 237 Sectoral / Thematic peers. This means the fund takes significantly different stock positions compared to its category peers.